Skip to main
AIM

AIM Stock Forecast & Price Target

AIM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AIM ImmunoTech Inc. has demonstrated a strong positive trajectory in clinical data, with initial results from its Phase 2 studies indicating potential therapeutic benefits of Ampligen in treating both post-COVID conditions and metastatic colorectal cancer. The continuous generation of favorable data from these studies is expected to serve as significant catalysts for the company's stock performance. Furthermore, the focus on addressing unmet medical needs in cancers and viral diseases positions AIM ImmunoTech favorably within the immuno-pharma sector, potentially enhancing investor confidence and market interest.

Bears say

AIM ImmunoTech Inc. reported a net loss of $3.3 million, significantly exceeding both internal and consensus estimates, indicating greater financial strain than anticipated. The company is also facing substantial risks related to its balance sheet and liquidity, as well as challenges in demonstrating the safety and efficacy of its product candidates in clinical trials which could hinder regulatory approvals and commercialization efforts. Additionally, AIM ImmunoTech must navigate a competitive landscape and shifting investor sentiment, factors that could further diminish prospects for securing suitable reimbursement and achieving long-term financial stability.

AIM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AIM ImmunoTech Inc (AIM) Forecast

Analysts have given AIM a Strong Buy based on their latest research and market trends.

According to 1 analysts, AIM has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AIM ImmunoTech Inc (AIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.